Discover more insights into Markers Initiative 마커 이니셔티브

Keywords frequently search together with Markers Initiative 마커 이니셔티브

Narrow sentence examples with built-in keyword filters

Markers Initiative sentence examples within Progression Markers Initiative



Mortality Risk in Older Adults: What the Nose Knows


Worse Cognitive Performance Predicts Increased Anxiety and Depressive Symptoms in Patients With Parkinson’s Disease: A Bidirectional Analysis

Markers Initiative sentence examples within markers initiative database



Optimization of Parameters for Quantitative Analysis of 123I-Ioflupane SPECT Images for Monitoring Progression of Parkinson Disease


Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)


Mortality Risk in Older Adults: What the Nose Knows



Worse Cognitive Performance Predicts Increased Anxiety and Depressive Symptoms in Patients With Parkinson’s Disease: A Bidirectional Analysis



A Risk Stratification Model for Early Cognitive Impairment After Diagnosis of Parkinson’s Disease



The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson’s Disease



Entorhinal Cortex Atrophy in Early, Drug-naive Parkinson’s Disease with Mild Cognitive Impairment



Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression



Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease



Optimization of Parameters for Quantitative Analysis of 123I-Ioflupane SPECT Images for Monitoring Progression of Parkinson Disease



Data-Driven Subtyping of Parkinson’s Disease Using Longitudinal Clinical Records: A Cohort Study



The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease



Predicting neuropsychiatric symptoms of Parkinson’s disease with measures of striatal dopaminergic deficiency



Predicting Early Stages of Neurodegenerative Diseases via Multi-task Low-Rank Feature Learning



Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort



Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales



Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder



Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson’s disease patients and its association with cognitive decline



Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease



Predict cognitive decline with clinical markers in Parkinson’s disease (PRECODE-1)



Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease



Clinical implications of early caudate dysfunction in Parkinson’s disease



Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)



Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures



Connectomics in NeuroImaging: Third International Workshop, CNI 2019, Held in Conjunction with MICCAI 2019, Shenzhen, China, October 13, 2019, Proceedings



Longitudinal and Multi-modal Data Learning for Parkinson’s Disease Diagnosis via Stacked Sparse Auto-encoder



Revision of Diagnosis in Early Parkinsonism with Abnormal Dopamine Transporter Imaging.



Empirical Functional PCA for 3D Image Feature Extraction Through Fractal Sampling



Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients



Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression



Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson’s disease



An MRI Atrophy Biomarker Predicts Global Prognosis in Early De Novo Parkinson’s Disease



Análisis de subtipos motores en la enfermedad de Parkinson: Registro Mexicano de Enfermedad de Parkinson (ReMePARK)



Swallowing and chewing difficulties are associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients



Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.



Automatic Classification and Monitoring of Denovo Parkinson’s Disease by Learning Demographic and Clinical Features



The Emerging Gait Dysfunction Phenotype in Idiopathic Parkinson’s Disease



Identifying Correlations among Biomedical Data through Information Retrieval Techniques


Learn more from Markers Initiative 마커 이니셔티브

Markers Initiative 마커 이니셔티브


Markers Initiative 마커 이니셔티브
Encyclopedia 백과사전